Dr. Overton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
820 N Chelan Ave
Wenatchee, WA 98801Phone+1 509-663-8711Fax+1 509-664-3417
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2011 - 2012- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2008 - 2011
New York Medical CollegeClass of 2008
Certifications & Licensure
OR State Medical License 2013 - Present
WA State Medical License 2014 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Start of enrollment: 2015 Jul 23
Publications & Presentations
PubMed
- 20 citationsMaintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study designMarkus Moehler, Min Hee Ryu, Mikhail Dvorkin, Keun Wook Lee, Hasan Şenol Coşkun
Future Oncology. 2019-02-01 - 12 citationsRegorafenib for treatment of advanced gastrointestinal stromal tumors.Lindsay C Overton, Michael Heinrich
Expert Opinion on Pharmacotherapy. 2014-02-08
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
